Setterwalls has advised Alligator Bioscience in connection with rights issue of approximately SEK 257 million

Setterwalls has advised Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 257 million. The rights issue was subscribed to approximately 121 per cent.

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden.